TrialBlood2021

BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.

Maissa Mhibik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.